Category Archives: News and Events

BriaCell Therapeutics Announces Proposed Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 ...

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s ...

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

ABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 ...

BriaCell Provides Update to its Board of Directors

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...

BriaCell Announces First Patient Dosed with Bria-OTS(TM) in Metastatic Breast Cancer Study

Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic ...

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust ...

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 ...

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data 55% of BriaCell patients[1] ...

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune ...